Mode
Text Size
Log in / Sign up

Postoperative radiotherapy improves survival and reduces recurrence in resected ESCCRadiotherapy After Surgery Improves Survival for Esophageal Squamous Cell Carcinoma

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider PORT for radically resected ESCC to improve survival and reduce recurrence, but weigh acute toxicity.

This meta-analysis evaluated the role of postoperative radiotherapy (PORT) in patients with radically resected esophageal squamous cell carcinoma (ESCC). The analysis pooled data from 11,385 patients, of whom 4,968 received PORT and 6,417 underwent surgery alone. The primary outcomes were overall survival (OS) and disease-free survival (DFS).

PORT significantly improved OS, with a hazard ratio of 0.74 (95% CI 0.69–0.80). It also significantly improved DFS and reduced locoregional recurrence (LRR), particularly in patients with high-risk features. The effect on distant metastasis was not reported.

Regarding safety, PORT increased acute toxicity, but the authors noted that toxicity was generally manageable. The recommended radiation dose to achieve optimal benefit is 50 Gy.

The meta-analysis included both randomized controlled trials and retrospective studies, which may introduce bias. The authors did not report specific limitations or funding sources. Clinicians should weigh the survival and recurrence benefits against the increased acute toxicity when considering PORT for individual patients.

How this fits prior evidence

This meta-analysis confirms and extends prior coverage on ESCC management. It aligns with the finding that neoadjuvant chemoimmunotherapy improves surgical outcomes in resectable ESCC, as both approaches aim to enhance locoregional control. It also complements the report on camrelizumab plus apatinib showing higher response rates and survival in treatment-naive patients, suggesting that multimodal strategies may benefit different patient subgroups. However, this analysis focuses on postoperative radiotherapy, a distinct intervention, and does not address immunotherapy-related adverse events like the sintilimab-associated GFAP astrocytopathy. The survival benefit (HR 0.74) provides quantitative support for PORT in radically resected ESCC, but the inclusion of retrospective studies tempers causal interpretation.

A large review of data from over 11,000 patients looked at the impact of adding postoperative radiotherapy (PORT) to surgery alone. The study focused on people who had already undergone surgery to remove esophageal squamous cell carcinoma. The goal was to see if adding radiation helped patients live longer and kept the cancer from returning.

The results showed that patients who received radiation after their surgery had significantly better overall survival rates compared to those who only had surgery. This treatment also improved disease-free survival and reduced the chances of the cancer returning in the local area, especially for patients with high-risk features.

While the extra radiation was found to be effective, it did increase some acute toxicity. However, these side effects were generally manageable for patients. To get the best results, the study suggests a specific radiation dose of 50 Gy. Because this analysis included both randomized and retrospective studies, you should talk with your doctor about how these findings apply to your specific treatment plan.

What this means for you:
Adding radiation after surgery can improve survival and reduce local recurrence for esophageal squamous cell carcinoma.

Common questions

Does adding radiation after surgery help patients live longer?

Yes, the study found that postoperative radiotherapy (PORT) significantly improved overall survival for patients with esophageal squamous cell carcinoma. This means that patients who received both surgery and radiation were more likely to survive compared to those who only had surgery.

Can this treatment reduce the chance of cancer coming back?

The study showed that adding radiotherapy after surgery helps improve disease-free survival. It specifically reduces locoregural recurrence, which is when the cancer returns in the same area. This benefit was especially noted for patients who had high-risk features.

Are there any side effects to using radiation after surgery?

The study reported that adding postoperative radiotherapy increases acute toxicity. However, these side effects were described as generally manageable. To achieve the best results, a radiation dose of 50 Gy is recommended.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
The role of postoperative radiotherapy (PORT) in patients with radically resected esophageal squamous cell carcinoma (ESCC) remains controversial. This meta-analysis aimed to evaluate the efficacy of PORT compared with surgery alone in terms of survival outcomes and toxicity. A systematic search was performed in PubMed, EMBASE, and the Cochrane Library from January 1990 to June 2025 for randomized controlled trials (RCTs) and retrospective studies (RSs) comparing PORT versus surgery alone in ESCC patients who underwent curative resection. Primary outcomes were overall survival (OS) and disease-free survival (DFS), reported as hazard ratios (HRs) with 95% confidence intervals (CIs). Secondary outcomes included locoregional recurrence (LRR), distant metastasis (DM), and treatment toxicity. Quality was assessed using the revised Cochrane risk-of-bias tool (ROB2) for RCTs and the Newcastle-Ottawa Scale (NOS) for retrospective studies. The Jadad scale was also applied for consistency with previous meta-analyses. Meta-regression and subgroup analyses were performed to explore heterogeneity. Thirty-five studies (8 RCTs, 27 RSs) comprising 11,385 patients (4,968 in the PORT group, 6,417 in the surgery alone group) were included. PORT significantly improved OS (HR = 0.74, 95% CI: 0.69–0.80, P  For patients with radically resected ESCC, PORT significantly improves OS and DFS and reduces LRR, especially in those with high-risk features. A radiation dose of 50 Gy is recommended to achieve optimal benefit. Although PORT increases acute toxicity, it is generally manageable. https://www.crd.york.ac.uk/PROSPERO/search, Identifier CRD420261400043.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.